(Q48694105)

14 February 2018

title

Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. (English)

1 reference

14 February 2018

main subject

schizophrenia

0 references

patient

0 references

cognitive dysfunction

1 reference

Xiang Yang Zhang

1

1 reference

14 February 2018

Jun Liang

2

1 reference

14 February 2018

Da Chun Chen

3

1 reference

14 February 2018

Mei Hong Xiu

4

1 reference

14 February 2018

Fu De Yang

5

1 reference

14 February 2018

Therese A Kosten

6

1 reference

14 February 2018

Thomas R Kosten

7

1 reference

14 February 2018

publication date

26 January 2012

1 reference

14 February 2018

published in

Psychopharmacology

1 reference

14 February 2018

volume

222

1 reference

14 February 2018

issue

2

1 reference

14 February 2018

page(s)

277-284

1 reference

14 February 2018

https://scigraph.springernature.com/pub.10.1007/s00213-012-2643-y

exact match

0 references

cites work

Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Cognition, dopamine and bioactive lipids in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Neurotrophic factors and the pathophysiology of schizophrenic psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Longitudinal study of symptoms and cognitive function in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Modulation of hippocampal synaptic transmission and plasticity by neurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Effects of stress throughout the lifespan on the brain, behaviour and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Essential role for TrkB receptors in hippocampus-mediated learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

What do we know about neuropsychological aspects of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Neurotrophins as synaptic modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Neuropsychological functioning in first-episode psychosis--evidence of specific deficits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Effects of stress on neurotrophic factor expression in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

Is it possible to be schizophrenic yet neuropsychologically normal?

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00213-012-2643-Y

21 January 2018

12 December 2020

Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia

1 reference

12 December 2020

Chlorpromazine equivalent doses for the newer atypical antipsychotics

1 reference

12 December 2020

A review of longitudinal studies of cognitive functions in schizophrenia patients

1 reference

12 December 2020

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

1 reference

12 December 2020

Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats.

1 reference

12 December 2020

Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment

1 reference

12 December 2020

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

12 December 2020

Investigation of serum BDNF levels in drug-naive patients with schizophrenia

1 reference

12 December 2020

Research Diagnoses for Tardive Dyskinesia

1 reference

12 December 2020

Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han.

1 reference

12 December 2020

The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia

1 reference

12 December 2020

Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia

1 reference

12 December 2020

10.1007/S00213-012-2643-Y

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018